Stockscreener 앱 받기
28.43
0.94%
-0.27
시간 외 거래:
28.78
0.35
+1.23%
Mbx Biosciences Inc 주식(MBX)의 최신 뉴스
MBX Biosciences (MBX) CFO John Smither files initial Form 3 - Stock Titan
MBX Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MBX Biosciences Chief Makes Bold Insider Move With Major Stock Buy - TipRanks
Company (NASDAQ: MBX) Form 144 — 10,000-share sale notice via Fidelity - Stock Titan
MBX Biosciences (NASDAQ:MBX) Shares Gap Up After Insider Buying Activity - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After Recent Share Price Pullback - simplywall.st
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 By Investing.com - Investing.com Canada
MBX Biosciences (NASDAQ:MBX) CEO Buys $525,585.00 in Stock - MarketBeat
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 - Investing.com UK
MBX Biosciences (MBX) CEO adds 18,500 shares via trust purchase - Stock Titan
MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus - Yahoo Finance
Baker BROS. Advisors LP Takes $4.86 Million Position in MBX Biosciences, Inc. $MBX - MarketBeat
Top MBX Biosciences (MBX) Competitors 2026 - MarketBeat
MBX Biosciences completes FDA meeting for Phase 3 trial design - Investing.com Nigeria
Ghisallo Capital Management LLC Takes $669,000 Position in MBX Biosciences, Inc. $MBX - MarketBeat
Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - MSN
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and REPRO-MED Systems (KRMD) - The Globe and Mail
MBX Biosciences Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Citizens reiterates Market Outperform on MBX Biosciences stock - Investing.com Nigeria
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - Sahm
Decoding MBX Biosciences Inc (MBX): A Strategic SWOT Insight - GuruFocus
Cowen Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Mar 2026 - Meyka
Truist reiterates Buy on MBX Biosciences stock, $50 target - Investing.com Nigeria
Truist reiterates Buy on MBX Biosciences stock, $50 target By Investing.com - Investing.com India
MBX Biosciences (NASDAQ: MBX) files $250M ATM sales agreement with Jefferies - Stock Titan
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target - Investing.com UK
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target By Investing.com - Investing.com Australia
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III By Investing.com - Investing.com Australia
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III - Investing.com India
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
MBX Biosciences : Company OverviewMarch 2026 - marketscreener.com
MBX: Advanced clinical pipeline and raised capital, supporting operations into 2029 - TradingView
MBX Biosciences 10-K: Operating loss $98.1M, Net loss $87.0M — cash runway into 2029 - TradingView
MBX Biosciences (NASDAQ: MBX) outlines precision peptide pipeline - Stock Titan
MBX Biosciences (NASDAQ: MBX) reports 2025 loss and cash runway into 2029 - Stock Titan
Inside MBX Biosciences’ $459M push into monthly obesity and hormone drugs - Stock Titan
MBX: Phase 3 for hypoparathyroidism starts in Q3, with major obesity and PBH data readouts ahead - TradingView
Is MBX Biosciences’ (MBX) Regulatory Win and Leadership Refresh Reframing Its Hypoparathyroidism Strategy? - simplywall.st
Stifel maintains MBX Biosciences (MBX) buy recommendation - MSN
Executives to engage with investors at key biotech events, MBX Biosciences outlines - Traders Union
MBX: FDA-aligned phase 3, strong pipeline, and funding secured for long-acting endocrine therapies - TradingView
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer - BioSpace
MBX Forecast, Price Target & Analyst Ratings | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
MBX Biosciences completes FDA meeting for Phase 3 trial design By Investing.com - Investing.com Canada
MBX Biosciences (NASDAQ:MBX) Stock Price Down 7.3%What's Next? - MarketBeat
MBX Biosciences to Initiate Phase 3 Trial of Once-Weekly Canvuparatide for Hypoparathyroidism Following Successful FDA End-of-Phase 2 Meeting - Minichart
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - The Manila Times
Truist reiterates MBX Biosciences stock rating after FDA meeting By Investing.com - Investing.com Canada
Weekly hypoparathyroidism drug set for 2026 Phase 3 after FDA talks - Stock Titan
Truist reiterates MBX Biosciences stock rating after FDA meeting - Investing.com Australia
1.20%
0.06%
자본화:
|
볼륨(24시간):